Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment

被引:0
|
作者
Zobeida Cruz-Monserrate
Christina L. Roland
Defeng Deng
Thiruvengadam Arumugam
Anna Moshnikova
Oleg A. Andreev
Yana K. Reshetnyak
Craig D. Logsdon
机构
[1] University of Texas,Department of Cancer Biology
[2] M. D. Anderson Cancer Center,Department of Surgical Oncology
[3] University of Texas,Physics Department
[4] M. D. Anderson Cancer Center,Department of GI Medical Oncology
[5] University of Rhode Island,undefined
[6] University of Texas,undefined
[7] M. D. Anderson Cancer Center,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the USA, accounting for ~40,000 deaths annually. The dismal prognosis for PDAC is largely due to its late diagnosis. Currently, the most sensitive diagnosis of PDAC requires invasive procedures, such as endoscopic ultrasonography, which has inherent risks and accuracy that is highly operator dependent. Here we took advantage of a general characteristic of solid tumors, the acidic microenvironment that is generated as a by-product of metabolism, to develop a novel approach of using pH (Low) Insertion Peptides (pHLIPs) for imaging of PDAC. We show that fluorescently labeled pHLIPs can localize and specifically detect PDAC in human xenografts as well as PDAC and PanIN lesions in genetically engineered mouse models. This novel approach may improve detection, differential diagnosis and staging of PDAC.
引用
收藏
相关论文
共 50 条
  • [1] Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
    Cruz-Monserrate, Zobeida
    Roland, Christina L.
    Deng, Defeng
    Arumugam, Thiruvengadam
    Moshnikova, Anna
    Andreev, Oleg A.
    Reshetnyak, Yana K.
    Logsdon, Craig D.
    SCIENTIFIC REPORTS, 2014, 4
  • [2] Targeting pancreatic ductal adenocarcinoma acidic microenvironment
    Cruz-Monserrate, Zobeida
    Roland, Christina L.
    Deng, Defeng
    Arumugam, Thiruvengadam
    Moshnikova, Anna
    Andreev, Oleg A.
    Reshetnyak, Yana
    Logsdon, Craig D.
    CANCER RESEARCH, 2015, 75
  • [3] Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma
    Pandey, Veethika
    Storz, Peter
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 473 - 482
  • [4] Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy
    Zhang, Yi-Fan
    Jiang, Shu-Heng
    Hu, Li-Peng
    Huang, Pei-Qi
    Wang, Xu
    Li, Jun
    Zhang, Xue-Li
    Nie, Hui-Zhen
    Zhang, Zhi-Gang
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (02)
  • [5] Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises
    Mei, Lin
    Du, Wei
    Ma, Wen Wee
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (03) : 487 - 494
  • [6] Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
    Skorupan, Nebojsa
    Dominguez, Mayrel Palestino
    Ricci, Samuel L.
    Alewine, Christine
    CANCERS, 2022, 14 (17)
  • [7] Targeting tumor microenvironment with gemcitabine is useful for the treatment of pancreatic ductal adenocarcinoma
    Tada, Motohisa
    Ijichi, Hideaki
    Miyabayashi, Koji
    Saoka, Yoshinari A.
    Mohri, Dai
    Ikenoue, Tsuneo
    Mikata, Rintarou
    Tawada, Katsunobu
    Ishihara, Takeshi
    Kanai, Fumihiko
    Imazeki, Fumio
    Omata, Masao
    Moses, Harold L.
    Yokosuka, Osamu
    CANCER RESEARCH, 2012, 72
  • [8] Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines
    Girish, Bala Prabhakar
    Dariya, Begum
    Mannarapu, Mastan
    Nagaraju, Ganji Purnachandra
    Raju, Ganji Seeta Rama
    SEMINARS IN CANCER BIOLOGY, 2022, 86 : 1155 - 1162
  • [9] Targeting mTOR in Pancreatic Ductal Adenocarcinoma
    Iriana, Sentia
    Ahmed, Shahzad
    Gong, Jun
    Annamalai, Alagappan Anand
    Tuli, Richard
    Hendifar, Andrew Eugene
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [10] Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma
    Singh, Gurkaranjot
    Kutcher, Drew
    Lally, Rajeshwar
    Rai, Vikrant
    CANCERS, 2024, 16 (11)